Last reviewed · How we verify
ORIYOMI OMOTOYOSI AKINYOTU — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Sulphadoxine-Pyrimethamine | Sulphadoxine-Pyrimethamine | marketed | Antifolate antimalarial | Dihydrofolate reductase; dihydropteroate synthase | Infectious Disease |
Therapeutic area mix
- Infectious Disease · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Centers for Disease Control and Prevention · 1 shared drug class
- Radboud University Medical Center · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for ORIYOMI OMOTOYOSI AKINYOTU:
- ORIYOMI OMOTOYOSI AKINYOTU pipeline updates — RSS
- ORIYOMI OMOTOYOSI AKINYOTU pipeline updates — Atom
- ORIYOMI OMOTOYOSI AKINYOTU pipeline updates — JSON
Cite this brief
Drug Landscape (2026). ORIYOMI OMOTOYOSI AKINYOTU — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/oriyomi-omotoyosi-akinyotu. Accessed 2026-05-17.